Remdesivir-Associated Significant Bradycardia: A Report of Three Cases

Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirvani, Maria, Sayad, Babak, Shojaei, Lida, Amini, Azadeh, Shahbazi, Foroud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, 2006- 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742862/
https://www.ncbi.nlm.nih.gov/pubmed/35082876
http://dx.doi.org/10.18502/jthc.v16i2.7390
_version_ 1784629791063801856
author Shirvani, Maria
Sayad, Babak
Shojaei, Lida
Amini, Azadeh
Shahbazi, Foroud
author_facet Shirvani, Maria
Sayad, Babak
Shojaei, Lida
Amini, Azadeh
Shahbazi, Foroud
author_sort Shirvani, Maria
collection PubMed
description Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients’ heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.
format Online
Article
Text
id pubmed-8742862
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Tehran University of Medical Sciences, 2006-
record_format MEDLINE/PubMed
spelling pubmed-87428622022-01-25 Remdesivir-Associated Significant Bradycardia: A Report of Three Cases Shirvani, Maria Sayad, Babak Shojaei, Lida Amini, Azadeh Shahbazi, Foroud J Tehran Heart Cent Case Report Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients’ heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects. Tehran University of Medical Sciences, 2006- 2021-04 /pmc/articles/PMC8742862/ /pubmed/35082876 http://dx.doi.org/10.18502/jthc.v16i2.7390 Text en Copyright © 2021 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Case Report
Shirvani, Maria
Sayad, Babak
Shojaei, Lida
Amini, Azadeh
Shahbazi, Foroud
Remdesivir-Associated Significant Bradycardia: A Report of Three Cases
title Remdesivir-Associated Significant Bradycardia: A Report of Three Cases
title_full Remdesivir-Associated Significant Bradycardia: A Report of Three Cases
title_fullStr Remdesivir-Associated Significant Bradycardia: A Report of Three Cases
title_full_unstemmed Remdesivir-Associated Significant Bradycardia: A Report of Three Cases
title_short Remdesivir-Associated Significant Bradycardia: A Report of Three Cases
title_sort remdesivir-associated significant bradycardia: a report of three cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742862/
https://www.ncbi.nlm.nih.gov/pubmed/35082876
http://dx.doi.org/10.18502/jthc.v16i2.7390
work_keys_str_mv AT shirvanimaria remdesivirassociatedsignificantbradycardiaareportofthreecases
AT sayadbabak remdesivirassociatedsignificantbradycardiaareportofthreecases
AT shojaeilida remdesivirassociatedsignificantbradycardiaareportofthreecases
AT aminiazadeh remdesivirassociatedsignificantbradycardiaareportofthreecases
AT shahbaziforoud remdesivirassociatedsignificantbradycardiaareportofthreecases

Ejemplares similares